- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02429557
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
Study Overview
Status
Intervention / Treatment
Detailed Description
Patients with autonomic failure are characterized by disabling orthostatic hypotension (low blood pressure on standing) due to severe impairment of the autonomic nervous system. Compression garments such as waist-high stockings and abdominal binders have been shown to improve orthostatic hypotension in these patients. The purpose of this study is to determine the hemodynamic mechanisms by which abdominal compression (up to 40 mm Hg) improve the standing blood pressure and orthostatic tolerance in these patients, and to compare them with those of the standard of care midodrine. The investigators will test the hypothesis that abdominal compression will blunt the exaggerated fall in stroke volume and the increase in abdominal vascular volume during head up tilt. This study will help us better understand the contribution of the abdominal veins to orthostatic hypotension and the mechanisms underlying this non-pharmacological therapeutic approach.
Participants will be studied in a tilt table in two separate days in a randomized, crossover fashion with sham abdominal compression (~5 mmHg) and active compression (~40 mmHg).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female patients,
- between 18-80 yrs.,
- with neurogenic orthostatic hypotension associated with primary autonomic failure (Parkinson Disease, Multiple System Atrophy and Pure Autonomic Failure). Orthostatic hypotension will be defined as ≥20 mmHg decrease in systolic BP or ≥10 mmHg of diastolic BP within 3 minutes on standing associated with impaired autonomic reflexes determined by autonomic testing in the absence of other identifiable causes (Freeman et al., 2011).
- Patients able and willing to provide informed consent.
Exclusion Criteria:
- Pregnancy.
- Significant cardiac, renal or hepatic illness, or with contraindications to administration of pressor agents or external abdominal compression will be excluded.
- Clinically unstable coronary artery disease, or major cardiovascular or neurological event in the past 6 months, and; other factors which in the investigator's opinion would prevent the subject from completing the protocol including clinically significant abnormalities in clinical, mental or laboratory testing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Abdominal compression and placebo pill
Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
|
Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
Other Names:
Placebo pill given 1 hour before the second heat up tilt
|
|
Sham Comparator: Sham abdominal compression and placebo
Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and placebo pill given 1 hour before the second head up tilt
|
Placebo pill given 1 hour before the second heat up tilt
Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
Other Names:
|
|
Experimental: Abdominal compression and midodrine
Abdominal compression with an inflatable abdominal binder (up to 40 mmHg) during head up tilt, and midodrine 2.5-10 mg PO given 1 hour before the second head up tilt
|
Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
Other Names:
Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
Other Names:
|
|
Active Comparator: Sham abdominal compression and midodrine
Sham abdominal compression with an inflatable abdominal binder (~5 mmHg) during head up tilt, and midodrine 2.5-10mg PO given 1 hour before the second head up tilt
|
Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
Other Names:
Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Stroke volume
Time Frame: an average of 15 minutes of head up tilt
|
Percent change from supine in stroke volume during head up tilt
|
an average of 15 minutes of head up tilt
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Systolic blood pressure
Time Frame: an average of 15 minutes of head up tilt
|
Change from baseline in systolic blood pressure during head up tilt
|
an average of 15 minutes of head up tilt
|
|
Splanchnic vascular volume
Time Frame: an average of 15 minutes of head up tilt
|
Percent change from supine in splanchnic vascular volume during head up tilt.
|
an average of 15 minutes of head up tilt
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Luis E Okamoto, MD, Vanderbilt University Medical Center
- Principal Investigator: Italo Biaggioni, MD, Vanderbilt University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Synucleinopathies
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Neurodegenerative Diseases
- Movement Disorders
- Basal Ganglia Diseases
- Primary Dysautonomias
- Autonomic Nervous System Diseases
- Orthostatic Intolerance
- Hypotension
- Multiple System Atrophy
- Hypotension, Orthostatic
- Pure Autonomic Failure
- Organic Chemicals
- Amines
- Alcohols
- Amino Alcohols
- Ethanolamines
- Midodrine
Other Study ID Numbers
- 140634
- 1R01HL144568-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple System Atrophy
-
iRegene Therapeutics Co., Ltd.RecruitingMultiple System Atrophy - Parkinsonian Subtype (MSA-P)China
-
Tokyo UniversityNobelpharmaRecruiting
-
Massachusetts General HospitalNational Institutes of Health (NIH); CurePSP FoundationRecruitingMultiple System Atrophy | Corticobasal Degeneration | Progressive Supranuclear Palsy | Corticobasal Syndrome | MSA - Multiple System Atrophy | MSA | Progressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Corticobasal Syndrome (CBS) | MSA-C | Multiple System Atrophy - Parkinsonian Subtype... and other conditionsUnited States
-
Beijing Tiantan HospitalRecruitingMultiple System Atrophy - Parkinsonian Subtype (MSA-P) | Multiple System Atrophy, MSAChina
-
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.Not yet recruitingthe Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P)
-
yilong WangNot yet recruitingMultiple System Atrophy - Cerebellar Subtype (MSA-C)China
-
Brigham and Women's HospitalBiohaven Pharmaceuticals, Inc.CompletedMultiple System Atrophy | Multiple System Atrophy, Parkinson Variant (Disorder) | Multiple System Atrophy, Cerebellar Variant | Multiple System Atrophy (MSA) With Orthostatic HypotensionUnited States
-
Synusight Biotech (Shanghai) Co., Ltd.Not yet recruitingParkinson's Disease (PD) | Multiple System Atrophy (MSA)China
-
Min Zhao,MDRecruitingMultiple System Atrophy - Parkinsonian Subtype (MSA-P) | Multiple System Atrophy - Cerebellar Subtype (MSA-C)China
-
Biocells MedicalNot yet recruitingMSA - Multiple System Atrophy | MSAPoland
Clinical Trials on Abdominal compression
-
Dalin Tzu Chi General HospitalCompletedColonic Polyp | Colonic AdenomaTaiwan
-
Seoul National University HospitalCompleted
-
Seoul National University HospitalCompletedHypovolemiaKorea, Republic of
-
The Clatterbridge Cancer Centre NHS Foundation...UnknownCancer of Stomach | Cancer, LungUnited Kingdom
-
Tianjin Medical University Cancer Institute and...Recruiting
-
Riphah International UniversityCompleted
-
Evergreen General Hospital, TaiwanThe Sepulveda Ambulatory Care Center, VAGLAHS, UCLA in the USA; E-Da Dachange...RecruitingColonoscopy | Colon Polyp | Manual Pressure | RepositioningTaiwan
-
Global Monitors, Inc.University of VirginiaCompleted
-
Changhai HospitalUnknownColorectal Adenoma | Colorectal PolypChina
-
Hopital Louis PradelUnknownFluid Overload | Hypovolemia | Diuretic ToxicityFrance